

Resource Summary Report

Generated by [NIF](#) on Sep 14, 2026

CD44

RRID:AB_2738518

Type: Antibody

Proper Citation

BD Biosciences Cat# 563971, RRID:AB_2738518

Antibody Information

URL: http://antibodyregistry.org/AB_2738518

Proper Citation: BD Biosciences Cat# 563971, RRID:AB_2738518

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD44

Description: This monoclonal targets CD44

Target Organism: mouse

Clone ID: IM7

Antibody ID: AB_2738518

Vendor: BD Biosciences

Catalog Number: 563971

Record Creation Time: 20231110T033526+0000

Record Last Update: 20260829T222136+0000

Ratings and Alerts

No rating or validation information has been found for CD44.

No alerts have been found for CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Geng S, et al. (2026) Krüppel-like factor 2 programs early exhausted T cell states and restrains antiviral immunity. *Immunity*, 59(5), 1306.

Wang H, et al. (2026) Targeting TMED4 enhances CD8+ T cell function and CAR T cell efficacy in solid tumors through the IRE1?-autophagy axis. *Science advances*, 12(24), eae0517.

Wang L, et al. (2025) Mucosal boosting increases protective efficacy of an influenza vaccine in mice. *iScience*, 28(6), 112721.

Cohen JA, et al. (2025) KMT2D coordinates antiviral CD4+ T cell responses through opposing effects on T follicular helper and cytotoxic gene expression. *Cell reports*, 44(6), 115775.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Corriveau J, et al. (2025) Inhibition of PAK2 in endothelial cells suppresses tumor angiogenesis and promotes immune sensitization through CXCL10. *Cell reports*, 45(1), 116840.

Vidal SJ, et al. (2025) Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. *Cell*.

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R? strengthens T cell-mediated anti-tumor therapies. *Cell reports. Medicine*, 5(10), 101747.

Gao X, et al. (2023) Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance. *Cell reports*, 42(4), 112314.

Vidal SJ, et al. (2023) Attenuated Mycobacterium tuberculosis vaccine protection in a low-dose murine challenge model. *iScience*, 26(6), 106963.

Rahman SMT, et al. (2022) Double knockin mice show NF-?B trajectories in immune signaling and aging. *Cell reports*, 41(8), 111682.

Mu Z, et al. (2022) mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. *Cell reports*, 38(11), 110514.

Dikiy S, et al. (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. *Immunity*, 54(5), 931.

Huang H, et al. (2021) In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8⁺ T cell fate decisions. *Cell*, 184(5), 1245.

Fitzgerald B, et al. (2021) A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. *Cell reports methods*, 1(5).